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ABSTRACT 
 
THE EFFECTS OF RED WINE AND GRAPE JUICE CONSUMPTION IN 
OVERWEIGHT INDIVIDUALS ON MULTIPLE HEALTH PARAMETERS 
(December 2010) 
 
Weng On Ho, B.S., University of California, Davis 
M.S., Appalachian State University 
Chairperson: Lisa McAnulty, Ph.D., R.D. 
INTRODUCTION: Red wine consumption may have potential health benefits due to 
the presence of polyphenolic compounds.  However, the literature is equivocal regarding 
specific mechanisms for positive health outcomes.  The purpose of this research was to 
investigate the effects of muscadine red wine and grape juice on weight, body fat, lipids, 
inflammation, and antioxidant capacity in overweight individuals.  METHODS:  In a 
randomized crossover design, 19 subjects consumed 300 mL of wine (WG) or grape juice 
(JG) for two weeks and acutely upon returning to the lab.  Blood was drawn at baseline, post 
two weeks, and acutely.  The statistical design was a 2 (treatments) x 3 (times) repeated 
measures ANOVA.  A paired t-test was used to compare differences in diet.  Results were 
analyzed using SPSS 16.0.  RESULTS: Overall weight gain occurred in both groups with 
treatment effect (P=0.044) and time effect (P=0.018). Significant weight gain was found in 
WG (P=0.027). Total fat mass percentage was not significantly different after treatments.   
C-reactive protein (CRP) and lipids were not affected by red wine or grape juice.  Ferric 
reducing ability of plasma (FRAP) significantly increased after acute, but not chronic, 
consumption of red wine (P<0.001).  Oxygen radical absorptive capacity of plasma (ORAC) 
did not change significantly for either treatment.  CONCLUSION: Adding wine or grape 
juice to the diets of overweight sedentary individuals, with no other dietary alterations, 
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resulted in significant weight gain.  Neither acute nor chronic consumption of red wine or 
grape juice altered blood lipids or reduced inflammation. However, acute consumption of red 
wine resulted in significant changes in antioxidant capacity which may confer potential 
benefits on health variables other than ones examined in the present study.    
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INTRODUCTION 
 
 
It is well known that France has lower rates of obesity and reduced incidence of 
mortality due to cardiovascular disease despite having a diet high in saturated fat.  This 
observation is known as the “French Paradox” (1).  A possible explanation for this 
phenomenon may be associated with the consumption of red wine by the French. Studies 
show that moderate red wine consumption may have potential health benefits due to its 
alcohol content and the substantial amounts of phenolic compounds present (2-4).  Research 
has shown individuals with moderate alcohol consumption, including red wine, reduce the 
risk of dying from heart disease by 40 %, increase high density lipoprotein (HDL) 
cholesterol, and promote other cardio-protective effects (5).  Polyphenols are a class of 
compounds found in plants that exhibit antioxidant characteristics.  Red wine polyphenolic 
compounds have been found to act as powerful vasodilators and help preserve the integrity of 
endothelial tissue (6). Polyphenols, such as resveratrol and quercetin, have been shown to 
increase serum antioxidant capacity, which may protect against damage caused by free 
radical production in the body, and prevent the increase of inflammatory agents and the 
oxidation of low density lipoprotein (LDL) (7, 8).  Excessive production of radical species 
can lead to atherosclerotic conditions which can promote development of multiple 
cardiovascular diseases (9). Compared to other types of juices, such as pomegranate juice 
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and acai juice, red wine has a higher antioxidant capacity (10). The objective of this research 
was to examine outcome effects on anthropometric measures, blood lipids, inflammation, and 
blood antioxidant capacity associated with chronic and acute consumption of muscadine 
grape juice and muscadine red wine.
3 
 
LITERATURE REVIEW 
 
 
Health Benefits of the Components of Red Wine 
Ethanol 
Ethanol has been shown to influence chronic illness risks (11). In recent studies, 
moderate alcohol consumption has been consistently shown to exert protective effects on 
heart disease (5, 12, 13). An increase in HDL cholesterol, caused by moderate alcohol 
consumption, was shown to reduce atherosclerotic disease risk (14). For diabetic patients, 
moderate ethanol intake is not generally contraindicated (15). Although moderate intake of 
ethanol was shown to have no effect on the glycemic control of patients with type 1 diabetes, 
it reduced fasting blood glucose concentrations of patients with type 2 diabetes (16).  
Conversely, the relationship between moderate ethanol intake and cancer risk is still 
very unclear. For example, in the Framingham Study (17), breast cancer risk was not 
particularly associated with wine, beer, or spirits consumption, while a study by Longnecker 
et al. (18) revealed that breast cancer risk was increased by one or two drinks of ethanol. 
Therefore, the relationship between ethanol consumption and chronic illness risks such as 
atherosclerotic cardiovascular disease, diabetes, and cancer varies qualitatively (15).  
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More than 50 epidemiological studies suggest that the effects of ethanol on overall 
mortality follow a J-shaped curve (15).  The low mortality rate given by moderate doses of 
ethanol is believed to be attributed to its protective effect on heart disease, while the high 
mortality rate resulting from high ethanol intake is attributed to its exacerbating effect on 
cancer and cirrhosis (19). In addition, the three types of alcoholic beverages affect mortality 
in a different way. Low-to-moderate intake of hard liquor implies an increased risk of all-
cause mortality, while the consumption of beer does not have a significant effect on mortality 
risk (11). However, moderate intake of red wine is associated with lower rates of mortality 
and appears to be protective in all populations studied (11, 15, 19). 
In short, although ethanol does not clearly indicate benefits against chronic diseases 
such as cancer and diabetes, regular consumption of any alcohol in moderate amounts seems 
to be beneficial to cardiovascular health, with the strongest evidence of this trend seen among 
wine-drinking populations (15). Populations that consume a moderate amount of red wine 
also have been observed to have lower rates of cancer, compared to those who consume 
similar quantities of other alcohol-containing beverages (15). In addition, epidemiological 
studies suggest there are other significant health properties of drinking red wine (19, 20). 
Obesity, one of the biggest health concerns in America, may be negatively associated with 
red wine consumption. Conditions and diseases associated with obesity include hypertension, 
hyperlipidemia, type ΙΙ diabetes, coronary heart disease, stroke, obstructive sleep apnea, 
asthma, orthopedic disorders, and certain cancers (21). The rising demand for safe and 
effective anti-obesity drugs has made red wine appealing to overweight individuals because it 
may reduce weight and body fat naturally without the side effects of prescription medications 
(22). Moderate red wine intake was shown to prevent an increase of body weight in rats (23). 
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A very recent study concluded that moderate amounts of red wine can elevate adiponectin 
concentration in vivo by 29.8 % (24). An increase in plasma concentration of adiponectin (an 
adipose-tissue-specific protein) has been shown to correlate negatively with  body mass 
index, glucose, insulin, and triglyceride plasma levels and positively with HDL and insulin-
stimulated glucose disposal (25). Adiponectin also has anti-inflammatory and anti-
atherogenic properties (25). The discovery of a significant increase in adiponectin levels by 
moderate red wine consumption strengthens the concept of red wine’s ability to exert health 
benefits. In addition, in populations where fruits and vegetables were limited, wine 
consumption showed a clear benefit over other forms of ethanol (19). Aside from the ethanol 
component in red wine, there are other constituents which may contribute health properties. 
 
Phenolics 
Wine is not simply grape juice with added alcohol (15). The fermentation process 
needed for wine making produces a variety of other chemically active ingredients (26). 
During the production of wine, organic acids and phenolics in the freshly pressed grape juice 
are converted into polyphenolics (phenolic acids and polyphenols) (26). Polyphenolics are 
responsible for the different tastes, colors, and mouthfeels of wine (26). According to the 
calculations of Paganga et al. (27), the antioxidant activity in 1 glass of red wine (150 mL) is 
equivalent to 12 glasses of white wine, 2 cups of tea, 5 apples, 5 portions (100 g) of onions, 
5.5 portions of eggplant, 3.5 glasses of black currant juice, 500 mL of beer, 7 glasses of 
orange juice, or 20 glasses of apple juice. The large content of phenolic compounds in red 
wine contributes to its properties of reducing disease risk, which is separate from the already 
protective effect of ethanol (15). 
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Polyphenolics can be classified as either flavonoids or non-flavonoids (28). 
Polyphenols are well known for contributing to the health benefits of red wine.  Flavonols, a 
subcategory of flavonoids, were shown to reduce damage on white blood cell DNA among 
type 2 diabetics (29). However, the flavonol studied was extracted from tea and onions 
instead of wine. Since the phenolic profiles of onion and red wine are different, distinguished 
differences may exist in their antioxidant properties or capacities (15). Little information 
exists on the effects of wine polyphenols on diabetes (15). 
Quercetin, which is a well-known red wine flavonol, has a wide spectrum of bioactive 
effects (30). These include its positive influences as an anti-inflammatory, antimicrobial, and 
antioxidant agent as well as its ability to regulate the immune system and the central nervous 
system (31-35). Quercetin also has specific anticancer properties including the inhibition of 
the growth of cancer cells derived from the stomach (36), colon (37), and breast (34) in 
humans. In mice, quercetin suppressed the growth and development of uterine cervical 
cancer (38), melanomas (39), and intestinal tumors (40). 
More recently, resveratrol, a non-flavonoid, has also been studied extensively. 
Resveratrol has been found to have protective effects on the cardiovascular system due to its 
ability to inhibit platelet aggregation (22) and to promote vasodilation (41). Resveratrol also 
possesses anti-carcinogenic properties (42). Results of in vitro studies using pharmacologic 
doses of resveratrol indicate protection of heart (43) and brain tissue (44) from oxidative 
stress while eliminating cancer cells (45, 46). In addition, resveratrol also improves insulin 
sensitivity in mice that are fed a high caloric diet by activating the SIRT 1 gene which 
mimics the effects of calorie restriction (47). Heavy doses of resveratrol are shown to be 
beneficial in decreasing obesity-related death by up to 31 % in mice (48). Obese mice that 
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received resveratrol extract not only remained as agile as lean mice but also lived longer than 
the obese mice that received the same high-calorie diet without resveratrol, with organs that 
also appeared normal. Researchers believe that resveratrol lowers the rate of diabetes, liver 
problems, and other diseases linked to obesity (48). Another possibility of why treated mice 
may have had longer life expectancy is that resveratrol possesses anti-viral properties which 
combat illness (49). Resveratrol was found to restrict the ability of viruses to replicate, 
reduce production of viral DNA, and increase the potency of some antiviral drugs (50-52). 
Resveratrol also possesses anti-inflammatory properties (53) which directly influence 
arthritis, Crohn’s disease, psoriasis, and has an association with the development of both 
cardiovascular disease and cancer (22). The anti-inflammatory properties of resveratrol have 
proven to be an effective inhibitor of the pro-inflammatory enzymes cyclooxygenase and 5-
lipoxygenase in mice (54, 55). These anti-inflammatory properties have shown a reduction of 
acute and chronic chemically-induced edema, lipopolysaccharide-induced airway 
inflammation, and inflammation associated with osteoarthritis (20, 22, 56, 57). A single dose 
up to 5 mg of resveratrol was shown to have no serious adverse health effects (58). These 
findings provide strong evidence of resveratrol’s biochemical capabilities, but the question is 
whether wine polyphenols exert the same effects in humans.  
 A central issue relevant to the interest in wine phenolics is the production of reactive 
oxygen species (ROS), including free radicals, an essential part of human metabolism (59). 
ROS can damage vital biological systems and are relevant in more than 100 disease states 
(60). The production of ROS, in amounts that overwhelm the antioxidant defense system, is 
known as oxidative stress (59). Chronic oxidative stress, caused by production of ROS, is 
strongly linked to numerous diseases which include cardiovascular disease (35). Therefore, it 
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is of great interest to know whether the plasma antioxidant effects of red wine consumption 
would be correlated with the changes in blood oxidative stress in the human body. 
 Most red wine antioxidant effects have been observed in vitro (26, 61, 62). Several 
studies examined measures in vivo and also demonstrated these antioxidant effects after a 
single ingestion of red wine and dealcoholized red wine (2-4, 63). However, the same 
antioxidant capabilities have not been demonstrated in other studies when the similar red 
wine beverages are consumed for a longer duration between 10 to 30 days (64-69). Therefore, 
it is still unclear whether red wine and/or dealcoholized red wine intake can increase plasma 
antioxidant capacity and prevent oxidation in vivo. Also, the effect of acute red wine or 
dealcoholized red wine consumption may be significantly different from the effect of chronic 
consumption. 
 
Summary of Current Literature 
Various clinical and experimental data suggest red wine components exert desirable 
effects on lipid profiles, inflammation markers, and other disease risk factors. Red wine 
contains an abundant amount of polyphenolic compounds which have been shown to provide 
numerous health benefits based on antioxidant properties. It is important to determine 
whether the health benefits are derived from ethanol, the polyphenols, or a synergistic 
combination of the two components in wine. It is also important to examine the difference 
between the health effects of acute ingestion of beverages with respect to the health effects of 
chronic ingestion of these beverages.     
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Development of the Research Design 
Subjects 
Overweight or obese individuals, aged 40 and over, were recruited in this research 
experiment to determine the effects of chronic (daily consumption for 2 weeks) and acute ( 1- 
h after consumption) consumption of 300 mL muscadine wine or grape juice on parameters 
of weight and body fat, blood lipids, C-reactive protein, and blood antioxidant capacity and 
phenols. The basis of this study is that older individuals exhibit more oxidative stress and 
inflammation than younger ones due to decreased immune function (70, 71). Subjects of at 
least 40 years of age were expected to display increased health benefits when compared to 
younger subjects. Individuals selected for participation in this study were overweight or 
obese because high body mass index (BMI) and obesity have been shown to be associated 
with early mortality (72).  
 
Wine and Grape Juice 
Muscadine wine was chosen because muscadine grapes may have a higher level of 
antioxidants and other nutrients than other grape species (73). Therefore, muscadine wine 
may have a greater potential for health benefits when compared to other wines. Three-
hundred mL of red wine or grape juice were consumed because most studies suggested that 
moderate consumption of red wine exerts optimal benefits (15). The U.S. Department of 
Agriculture defines a “moderate” consumption of wine to be 150 mL for women and 300 mL 
for men on a daily basis (74). 
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Procedure 
The subjects were randomly assigned to receive 14 days of daily consumption of 
either 300 mL red wine or 300 mL grape juice, followed by an identical acute amount of the 
initial drink. Subjects then stopped drinking for 2 weeks during a washout period. The whole 
cycle was repeated with the opposing treatment (wine treatment switched to grape juice 
treatment and vice versa). By doing this, the subjects served as their own control. Therefore, 
confounding variables were significantly reduced. 
 
Outcome Measures 
Plasma antioxidant activities were examined due to the relationship with the 
development of atherosclerosis, inflammatory diseases, and cancer (46). Biomarkers of 
inflammation were examined because inflammation has been shown to be a direct cause of 
diseases such as arthritis, Crohn’s, and psoriasis, and may have a role in the development of 
cancer and cardiovascular disease (22). Changes in body weight and composition were also 
investigated along with red wine consumption to determine the physical effects, if any, of red 
wine consumption.  
Antioxidant Capacity 
Oxygen radical absorbance capacity (ORAC) and ferric reducing ability of plasma 
(FRAP) were used to measure plasma antioxidant capacity. The antioxidant activity in wine 
depends on various factors which include the physical properties of the substrates, stages and 
conditions of oxidation, and the different phases of antioxidants (75). ORAC and FRAP 
correlated significantly when used for measuring the antioxidant capacity of phenolics in 
processed commodities such as rapeseed and olive oils (76). Since red wine is processed 
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from grapes, this combined method would seem advantageous. The ORAC method, initially 
developed by Cao et al. (60), measures the antioxidant activities on hydrophilic chain-
breaking antioxidant capacity against peroxyl radical. The ORAC assay was significantly 
improved by Ou (77)  and co-workers when fluorescein was used as the fluorescent probe. 
The absorbance value given by the high intensity of fluorescence from fluorescein will be 
used as the quantified units in this assay.  During the antioxidant capacity assessment, a 
peroxyl-radical-generating chemical called AAPH will be introduced to samples, blank 
solutions with no antioxidant capacity, and Trolox with known antioxidant capacity (78). 
When the fluorescein is oxidized by the peroxyl radicals generated by the AAPH, its 
fluorescence will be lost and the absorbance measured will be lowered and a decreased 
reading of absorbance will result (77).  Antioxidants, if present in the sample, will provide an 
inhibition of the radical action by the AAPH and create a the lag period  before onset of 
peroxidation (60). By comparing the area under the fluorescence decay curve (AUC) of the 
sample with that of the blank, the protective effect of the antioxidant present in the sample 
can be quantified after the assay has been calibrated with the Trolox (77). The advantage of 
the ORAC assay is that it accounts for both inhibition percentage and the length of inhibition 
time of the free radical action by antioxidants (60). On the other hand, Benzie and Strain 
developed the FRAP assay which measures the direct ability of antioxidants to reduce a ferric 
complex to the ferrous complex in acidic conditions (79). The resulting reduced ferrous 
complex (blue in color) is measured spectrophotometrically at 593 nm. This value reflects  
the total reducing capacity of electron-donating antioxidants (53). Both ORAC and FRAP 
together allow for an effective way of measuring the antioxidant capacity of red wine. The 
advantages seen in one method adjust for the inadequacy of the other method.  
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Inflammation Status 
C-reactive protein (CRP) was used as the main indicator of inflammation status.  CRP 
is an acute phase protein that is elevated during inflammatory stress (80). It has been 
suggested that testing CRP levels in the blood may be an additional way to assess 
cardiovascular disease risk. Studies indicate that an increase in CRP is associated with 
increases in chronic disease (81). This correlation is most commonly seen in individuals who 
smoke, have hypertension, atherogenic lipoproteins, and hyperglycemia (81). In healthy 
young adults, high CRP levels are positively correlated with oxidative stress (82, 83). 
Body Composition 
A Dual Energy X-ray Absorptiometry (DEXA) machine was used in our study for 
analyzing potential changes in body composition. Compared to skin fold measurements, 
DEXA, the most commonly used anthropometric assessment of body fat, provides a more 
accurate measurement of body composition because of its precision (76).  
 
Significance of the Study 
Compared to previous studies which looked at plasma antioxidant status and/or 
indices of oxidative damage in red wine and/or dealcoholized wine, this study was the first to 
incorporate all the stated parameters (4, 84, 85). The design of the study will strengthen and 
expand the scope of the body of knowledge about red wine consumption.
13 
 
METHODOLOGY 
 
 
This study was approved by the Institutional Review Board and the University 
Research Council at Appalachian State University (Appendix A). 
 
Subjects: 
Twenty-six volunteers who were overweight or obese (BMI >24.9), at least 40 years 
old, non-smoking, and were not on prescription medications were recruited (Appendix B). 
All volunteers were infrequent consumers of alcohol, i.e. they consumed less than three 
alcoholic drinks per every two weeks. Volunteers were randomized to a wine consumption 
(WG) group or grape juice (JG) group.  
 
Study Design 
A diagram of the study design can be found in Appendix C. Volunteers were 
instructed to stop consuming fruits and fruit juices three days before coming in for testing 
and orientation.  Drug and alcohol use were prohibited 24 hours prior to reporting for each 
visit. Volunteers were also instructed to fast for at least eight hours prior to reporting to the 
lab. All volunteers visited the ASU lab four times throughout the study.  At baseline 
orientation, health questionnaires (Appendix D) and consent forms (Appendix A) were 
obtained. Height and weight were measured, and body composition was assessed by 
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bioelectrical impedance analysis (BIA) and DEXA. Blood samples (blood sample A) were 
drawn. 
 Subjects were instructed on how to adhere to the dietary restrictions. Herbal 
medicines, medications, or large-dose vitamin/mineral supplements (above 100 % of 
Recommended Dietary Allowances) were not allowed during the study period.  Volunteers 
were encouraged to maintain normal dietary patterns during the study. Red wine was given to 
the WG, and grape juice was given to the JG. At home, the WG group consumed two 150 
mL servings of wine per day for two weeks, and the JG group consumed grape juice with the 
same number of servings, serving size, and duration as the WG group. Subjects were asked 
not to consume other alcoholic beverages, grapes, or grape products during the study. 
Subjects were also taught to use a 3-day diet record for two weekdays and one weekend day 
during the treatment weeks (Appendix E). 
On their second visit, two weeks after treatment, 3-day diet records were collected to 
analyze the diet of each subject. Weight, percent body fat, and blood (blood sample B) were 
also obtained. Each subject then consumed a single 300 mL serving of either red wine or 
grape juice, depending on which group they belonged to. Another blood draw (blood sample 
C) was taken precisely one hour after consumption. To ensure safety, subjects remained in 
the lab for one hour after the acute consumption and were given a small meal before leaving. 
Subjects then had a washout period in which they stopped drinking wine or grape juice for 
two weeks. 
  On their third visit, weight, percent body fat, and blood were obtained. Then, the 
whole cycle was repeated with the opposing treatment for each subject (wine treatment 
switched to grape juice treatment and vice versa) for two weeks (blood samples D, E, and F 
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were then collected). Another set of 3-day diet records were obtained.  The fourth visit’s 
protocols were performed in the same way as the second visit.  
 
Wine and Grape Juice Samples 
Hatteras Red wine was provided by Duplin Winery (Rose Hill, NC). This type of red 
wine is made from muscadine grapes. Muscadine juice was provided by D’Vine Foods 
(Elizabethtown, NC). Heat and direct sunlight were avoided when storing the red wine and 
grape juice. Once opened, the wine and juice were stored in a refrigerator. 
 
Assessment Protocol 
Height  
Height was measured by a wall-mounted stadiometer. All shoes were taken off. The 
subject was asked to stand with heels together, arms to the side, legs straight, shoulders 
relaxed, and head in the Frankfort horizontal plane. The subject had to touch his/her buttocks, 
shoulder blades, and back of the head against the vertical surface of the stadiometer as much 
as possible.  The subject was asked to inhale a deep breath, hold the breath and maintain an 
erect posture. Measurement was taken at this time with the headboard lowered on the highest 
point of the head. Enough pressure was applied to compress the subject’s hair during 
measurement. All readings were corrected to the nearest inch.  
Weight and Body Composition 
BIA was used to assess weight and body fat percentage. Before arriving to the lab for 
testing, subjects were advised to drink enough water to prevent dehydration. Subjects stood 
on the scale barefoot and with minimal clothing. All readings were measured in pounds and 
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converted to kilograms for interpretation. DEXA was used to further assess total fat mass 
percentage and abdominal fat percentage. 
Blood 
Blood draws were done by venipuncture by trained technicians. Needle disposal 
boxes were available for all technicians. Two 5 mL EDTA tubes of blood were drawn for 
FRAP and ORAC.  One 5 mL serum-separator tube (SST) of blood was collected for 
assessing C-reactive protein (CRP). The SST tubes were allowed to sit for 20 minutes to 
allow blood to clot.  Blood tubes were then centrifuged within two hours at 3000 rpm for ten 
minutes at 3 ˚C. Plasma collected for analysis of FRAP and ORAC was aliquoted into snap-
top tubes (0.5 mL) and frozen using liquid nitrogen. The tubes were then stored at –80 ˚C for 
further analysis. All blood collected was disposed in red biohazard bags after analyses. 
Blood lipids and CRP 
Blood tubes were delivered to the biochemistry laboratory at Charles A. Cannon Jr., 
Memorial Hospital located in Linville, North Carolina to assess CRP and blood lipids using 
automated procedures. 
Oxygen Radical Absorbance Capacity (ORAC)  
The ORAC method works by reacting the samples with a fluorescent probe to form a 
non-fluorescent product that directly measures the antioxidant activities of chain-breaking 
antioxidants (76). The materials and methods for the ORAC assay were adapted from the 
method of Ou et.al (77). Twenty µL of sample, blank, and Trolox standard solutions were 
pipetted into appropriate wells on a microplate. Two hundred µL of fluorescein working 
solution were also pipetted into one of the wells. The microplate was then placed into a BMG 
Flurostat Galaxy/Optimal Plate Reader for analysis. Fluorescence readings at cycle i (fi) were 
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obtained from the machine. Relative Area under the Curve (relative AUC) was calculated by 
using the equation [AUC = (0.5 + f5 / f4 + f6 / f4 + f7 / f4 + … + fi / f4) × Cycle], while net Area 
Under the Curve (net AUC) was obtained by subtracting the AUC of the blank from that of a 
sample. The final ORAC values were calculated by using a quadratic regression equation (y 
= a + bχ + cχ
2
) between the Trolox concentration (µM) and the net AUC. The quadratic 
regression was used in the range of 6.25-50 µM Trolox. Data were expressed as micromoles 
of Trolox Equivalents per liter of sample (µmol TE/L). 
Ferric Reducing Ability of Plasma (FRAP) 
FRAP assay measures the direct ability of antioxidants to reduce a ferric complex to 
the ferrous complex in acidic conditions (75). The materials and methods for the FRAP assay 
were adapted from the method of Benzie and Stain (79). Blank, sample, and ascorbate 
standard tubes were made by adding 100 µL of plasma sample, deionized water, and 
ascorbate standard, respectively, to 3 mL of FRAP reagent and vortexed. Tubes were 
incubated at 37 ˚C for four minutes. The absorbance was then measured at 593 nm 
immediately after incubation using a spectrophotometer. Plasma reducing potential was 
reported as ascorbate acid equivalents (µmol Ascorbate/L) based on the reference curve of 
ascorbate concentration. One µmol ascorbate was expressed as one reducing equivalent.   
 
Data Analyses 
Statistical tests were performed using SPSS 16.0 for Windows (SPSS Inc., Chicago, 
IL, USA). The design was a 2 (treatments) x 3 (times) repeated measures ANOVA. ORAC 
and FRAP values were expressed as mean ± standard estimated mean (SEM), and other data 
were expressed as mean ± standard deviation (SD). A P-value of ≤0.05 was considered 
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statistically significant. A paired t-test was employed to determine if there were differences 
between subject characteristics. The three-day diet records were analyzed using Food 
Processor SQL software (ESHA Research, Salem, OR, USA). Any data with a z-score ± 2.5 
were considered outliers and were excluded from statistical analyses.
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RESULTS 
 
 
Of the 27 original subjects, 19 completed all stages of the study. Subject 
characteristics are presented in Table 1. Subjects ranged in age from 40 to 58, with six 
overweight and 13 obese. Table 2 shows the weight change in the wine and grape juice 
groups. Overall weight gain occurred in both groups with treatment effect (P=0.044) and 
time effect (P=0.018). Subjects who drank wine gained significantly more weight (P=0.027). 
However, Table 3 shows that total fat mass percentage was not significantly different after 
treatments. CRP and blood lipids were also not significantly changed by either treatment as 
seen in Table 4 and Table 5. Figure 1 shows that plasma ORAC was unchanged by either 
treatment. However, Figure 2 shows that FRAP significantly increased after acute, but not 
chronic, consumption of red wine (P<0.001). All raw data are presented in Appendix F. 
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Variable Treatment  
Number 19 
Gender 8  Males, 11 Females 
Age (yr) 48.79 ± 5.29 
Height (m) 1.68 ± 0.09 
Body mass (kg) 90.90 ± 15.10 
BMI (kg/m
2
) 32.01 ± 3.85 
Values are means ± standard deviations. 
 
Table 1. Baseline Characteristics of Subjects 
 
 
 
 
 
 
Table 2. Weight Change after Two Weeks of Daily Consumption of Red Wine and Grape 
Juice  
 
 
 
 
 
 
Table 3. Percent Total Fat Mass Change after Two Weeks of Daily Consumption of Red 
Wine and Grape Juice  
Values are means ± standard deviations 
  
Baseline Percent Total 
Fat Mass (%) 
End Percent Total Fat 
Mass (%) 
Change in Percent Total 
Fat Mass (%) 
Wine Group 36.78 ± 6.89 36.33 ± 6.36 - 0.45 ± 1.56 
Grape Juice Group 36.51 ± 6.70 36.82 ± 6.34 +0.31 ± 1.11 
  Treatment Time Interaction 
P-value 0.565 0.759 0.074 
  
Baseline 
Weight (kg) 
End      
Weight (kg) 
Change in 
Weight (kg) 
Post Hoc t-test:                                   
End Weight (kg) -Baseline Weight (kg) 
(Sig. 2-tailed) 
Wine Group 90.97 ± 15.06 91.56 ± 15.20 0.59± 1.08 0.027 
Grape Juice Group 91.65 ± 15.33 91.88 ± 15.49 0.23 ± 0.84 0.249 
  Treatment Time Interaction   
P-value 0.044 0.018 0.256   
Values are means ± standard deviations 
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Paired Differences 
t 
Sig.  
(2-
tailed) Mean 
Std. 
Deviation 
Wine Group End Triglycerides - Baseline Triglycerides (mg/dL) 12.45 31.44 -1.314 0.218 
Grape Juice Group End Triglycerides - Baseline Triglyceride (mg/dL) 0.29 31.05 -0.039 0.969 
Wine Group Baseline Triglycerides - Grape Juice Group Baseline 
Triglycerides (mg/dL) 
10.50 38.25 1.027 0.323 
Wine Group End Triglycerides - Grape Juice Group End Triglycerides 
(mg/dL) 
18.57 40.79 1.703 0.112 
Absolute Mean Change of Triglycerides of Wine Group - Absolute Mean 
Change of Triglycerides of Grape Juice Group (mg/dL) 
12.40 62.17 -0.631 0.544 
 
 
 
 
 
Table 4. Changes in C-Reactive Protein and Lipid Profile after Two Weeks of Daily 
Consumption of Red Wine and Grape Juice 
 
Table 5. Post Hoc t-test of Significant Treatment Effects on Triglycerides 
 
 
 
 
 
 
 
 
  
    Wine Group Grape Juice Group  P-value 
CRP (mg/L)   Treatment = 0.774 
 
Baseline 3.77 ± 2.61 3.84 ± 2.68 Time = 0.194 
 
After Two Weeks of Consumption 4.14 ± 2.96 4.31 ± 3.21 Interaction = 0.894 
Total Cholesterol (mg/dL) 
 
Treatment = 0.219 
 
Baseline 216.54 ± 34.71 211.15 ± 36.42 Time = 0.735 
 
After Two Weeks of Consumption 215.31 ± 32.49 209.38 ± 35.29 Interaction = 0.932 
HDL (mg/dL) 
 
Treatment = 0.572 
 
Baseline 47.31 ± 14.12 47.54 ± 14.25 Time = 0.440 
 
After Two Weeks of Consumption 47.00 ± 15.66 45.69 ± 13.77 Interaction = 0.373 
LDL (mg/dL) 
 
Treatment = 0.906 
 
Baseline 141.82 ± 28.89 139.36 ± 29.99 Time = 0.101 
 
After Two Weeks of Consumption 133.09 ± 24.76 136.73 ± 30.31 Interaction = 0.418 
Triglycerides (mg/dL) 
 
Treatment = 0.028 
 
Baseline 135.60 ± 32.87 121.10 ± 42.79 Time = 0.262 
 After Two Weeks of Consumption 147.90 ± 45.75 121.00 ± 31.95 Interaction = 0.544 
Values are means ± standard deviations. 
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Values are means + standard errors of the means 
Figure 1. Changes in Oxygen Radical Absorbance Capacity (ORAC). 
 
 
 
Values are means + standard errors of the means  
Figure 2. Changes in Ferric Reducing Ability of Plasma (FRAP). 
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DISCUSSION 
 
 
According to the Centers for Disease Control and Prevention, coronary heart disease 
(CHD), remains the leading cause of death in both men and women in the United States (86). 
Both epidemiological and experimental studies have shown that mild-to-moderate alcohol 
consumption, particularly red wine, can reduce incidence of mortality from CHD. The 
possible protective effects of red wine consumption on other leading causes of death, 
including various cancers and diabetes, have been well documented in research. The majority 
of research attributes the health benefits of red wine consumption to the alcohol and phenolic 
compounds present in red wine. Similarly, grape juice contains many of the same 
biologically active phenolic compounds found in red wine and may also contribute to the 
prevention of many diseases related to oxidative stress, such as atherosclerosis and 
Parkinson's disease (87).  
The present study sought to investigate the effects of red wine and grape juice 
consumption on blood antioxidant capacity, blood lipids, inflammatory biomarkers, weight 
change, and body composition. We hypothesized that, following the consumption of both 
beverages, there would be increased plasma antioxidant capacity through the increased 
presence of polyphenolic compounds.  It follows that increased antioxidant capacity would 
reduce the chance of lipoprotein oxidation and in turn ultimately reduce atherogenesis. 
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Further, we expected a decrease in CRP due to reduced inflammatory reaction. 
Additionally, as alcohol was introduced into the subject’s diet, we hypothesized that there 
would be an increase in HDL in the wine group. 
 
The Effect of Red Wine and Grape Juice Consumption on Plasma Antioxidant 
Capacity 
 
Utilizing the FRAP assay, this study demonstrated that acute consumption of red 
wine, but not grape juice, resulted in a significant increase in plasma antioxidant capacity. 
This is in agreement with the majority of research which shows that red wine increases 
antioxidant capacity compared to grape juice. The difference in antioxidant capacity between 
red wine and grape juice consumption may be due to the amount of antioxidant present. 
Therefore, it is crucial to examine the antioxidant content of both beverages. The 
compositional information of the red wine and the grape juice used is available for review in 
Appendix G. A 300 mL serving of red wine provides approximately 87 mg of resveratrol. 
We were, unfortunately, unable to obtain the antioxidant or resveratrol information about the 
grape juice from the manufacturer.  
The phenolic composition of the grape juice can be significantly affected during 
grape juice production, especially when grapes are crushed and pressed (88). Besides, the 
commercial grape juice-making process employs clarifying agents and filters which can 
decrease resveratrol levels (89). Resveratrol is also likely to be destroyed during commercial 
pasteurization because it is unstable to light, heat, and wet-heating (90). In contrast, total 
phenolic content of wine was shown to increase rapidly as it underwent the fermentation 
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process and continued to increase gradually as the wines aged in barrels (91). Furthermore, 
the occurrence of phenolic substances in wines was not only a consequence of their 
extraction from grapes during winemaking (92). During fermentation, the complex polymeric 
and glycosidic phenolic substances present in grapes break down into monomeric forms and 
thus become relatively easier to be degraded by digestive juices in human intestine (93). For 
all of the above reasons, wine is very likely to have an increased antioxidant capacity when 
compared to grape juice. 
However, it is not yet clear to what extent these compounds are absorbed in humans 
in a metabolically active form and affect plasma antioxidant capacity (88).  Hence, further 
research needs to be conducted to determine the relationship between the phenolic profile in 
grape-derived beverages and their effect on plasma antioxidant capacity.  Dietary 
polyphenolics are substrates for a number of enzymes in the small intestine and in the liver 
(94). They are usually ingested in larger forms as glycosides (94).  Some glycosides can be 
absorbed intact in the small intestine using the sodium-dependent glucose transporter 1, 
although most dietary polyphenolics need to be transformed into smaller aglycones by 
various intestinal enzymes before passing the gut barrier.  Conjugation will then immediately 
occur in the gut barrier (95). These conjugates are further metabolized in the liver (95). On 
the other hand, the polyphenols left in the intestinal lumen are subjected to hydrolysis and 
degradation in the colon due to the activity of enzymes of the colonic microflora, causing the 
destruction of the flavanol structure and the formation of simpler phenolic compounds (94). 
These complex breakdown, conjugation, and degradation activities that happen after 
ingestion of dietary polyphenolics influence the bioactivities of the compound and their 
subsequent effect on plasma antioxidant capacity. Careful examination should be done in 
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future studies to investigate the relationship between the types and amount of polyphenolics 
in grape-derived beverages and their effect on plasma antioxidant capacity. 
A possible explanation for different effects observed between the two beverages 
could be due to the presence of alcohol in red wine. Antioxidant status is the result of the 
interaction of many different compounds and systemic metabolic interactions (96). The 
absorption of antioxidants, their metabolic endpoint, and availability for antioxidant 
protection in humans are not fully understood (96). A review by Manach and co-workers (97) 
highlighted that polyphenols found in the fruits and vegetables most commonly consumed in 
the human diet are not necessarily the most active within the body due to the absence of 
ethanol. Our study demonstrated the different effects observed following grape juice and 
wine consumption. Since the main difference between red wine and grape juice is the 
presence of alcohol, we speculate that the remarkable increase in the antioxidant capacity 
followed by acute red wine consumption is due to the presence of alcohol in the wine, which 
might have enhanced the absorption and/or mechanism of the phenolic compound.  
It is important to note that although this study utilized both the ORAC and FRAP 
assays to assess serum antioxidant capacity, only FRAP changed significantly.  It is not 
surprising to see different results in the ORAC and FRAP assays. The results of these two 
assays cannot be compared directly, as the assays are based on different underlying 
mechanisms utilizing different radical or oxidant sources, and thus generate different values 
(98). In short, the ORAC assay has more biological relevance to the antioxidant efficacy in 
vivo. ORAC is able to assay both the hydrophilic as well as lipophilic antioxidants including 
enzymes, large molecules such as albumin, small molecules including ascorbic acid, uric 
acid, tocopherol, polyphenols, and hormones such as estrogen (98). Therefore, a change in 
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the antioxidant activity provided by a single specific antioxidant, such as a wine 
polyphenolic, may not be detected by ORAC due to the activity other antioxidants. On the 
other hand, the FRAP assay is used to measure hydrophilic and non-enzymatic antioxidants 
such as ascorbic acid, alpha-tocopherol, beta-carotene and uric acid. Because of this property, 
the increase in antioxidant capacity measured in our study can be attributed to more specific 
antioxidants that can only be detected by FRAP.  Furthermore, the FRAP assay can 
underestimate antioxidant capacity as it assumes that redox reaction can be completed within 
the assay time (99).  Possible underestimation by FRAP strengthens our conclusion about the 
ability of red wine consumption on increasing plasma antioxidant capacity. 
As physical activity was not monitored for the study duration, it represents a potential 
limitation in the study design. Previous research has suggested that physical activity can 
improve antioxidant capacity (100, 101).  It is important that future research take physical 
activity into account.  
 
The Effect of Red Wine and Grape Juice Consumption on Inflammatory Biomarkers of 
Atherosclerosis 
 
According to the American Heart Association, CRP is an acute phase protein that is 
elevated during inflammatory stress (81). Therefore, testing for elevated CRP levels in the 
blood may be an additional way to assess cardiovascular disease risk, as atherosclerosis is an 
inflammatory disorder (102). Another research study found that serum concentrations of CRP 
were reduced by 21 % after adding 30 g of ethanol from wine for 28 days (103). The 
decrease in CRP level was attributed to the non-alcoholic compounds in the wine, mainly 
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polyphenols (103). In contrast to these results, this study showed that serum concentration of 
CRP was not significantly changed. Instead of a decrease in the CRP level, there was actually 
a slight non-significant increase in CRP in both treatment groups. The increase of CRP levels 
is likely related to the weight gain contributed by the added calories.  Weight gain was shown 
to be positively correlated with CRP level in other studies (104, 105). Besides, as low 
exercise levels are associated with slightly elevated CRP (106), the physical activity of the 
subjects represents a potential confounding factor in determining if CRP levels are 
significantly affected through alcohol consumption. 
 
The Effect of Red Wine and Grape Juice Consumption on Lipid Profiles 
 
A previous study using red wine from the same winery demonstrated that chronic red 
wine consumption was effective in reducing triglyceride levels (107).  However, in contrast 
to this study, triglyceride levels increased after two weeks of wine consumption (P=0.028). 
Careful consideration was taken to improve subject compliance.  Subjects were instructed to 
fast for at least eight hours prior to reporting to the lab for each blood draw in an effort to 
eliminate confounding variables. However, study subjects did not always remember to fast 
prior to blood draws. Because triglyceride levels change dramatically in response to meals 
(108), a possible explanation that the non-significant post-hoc increase in triglyceride levels 
(Table 4 and 5) could be related to subject compliance rather than red wine or grape juice 
supplementation.  
On the other hand, HDL, LDL, and cholesterol levels do not respond as quickly as 
triglycerides to diet or lifestyle changes. Changes may take up to months to be seen. 
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Research shows that cholesterol profile of each individual has different physiological 
responsiveness from diet and lifestyle (109). Cholesterol profile changes in 3-4 weeks 
through diet are considered to be highly responsive (109). Some changes may take up to 3-6 
months to be seen.  
HDL was not altered in our study.  There are numerous studies that have 
demonstrated that moderate amounts of alcohol (10-40 g/day) are a protective factor against 
CHD (110-112). The mode is most likely due to its ability to increase protective HDL 
cholesterol (113). In our study, although no significant changes were seen on HDL, it is 
speculated that red wine or grape juice supplementation for a longer period of time may 
increase HDL. 
A slight decrease in LDL and cholesterol values in both red wine and grape juice 
treatment groups after two weeks was observed in our study. These findings are in agreement 
with a study by Yugarani and coworkers (114) that found that a high fat diet with daily 
supplementation of tannic acid, a phenol found in high concentrations in muscadine grape 
and muscadine grape products, lowered LDL and total cholesterol by 29.6 % and 33.31 %, 
respectively, after 10 weeks of supplementation. Auger et al. (115) demonstrated that 
hamsters fed an atherosclerotic diet with a 8-week red wine phenolic extract supplementation 
had lower total cholesterol levels compared to those that were not under supplementation. 
Therefore, it is speculated that red wine or grape juice supplementation for a longer period of 
time may lower LDL and cholesterol to more significant levels.  
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The Effect of Red Wine and Grape Juice Consumption on Weight Change 
 
Another observation of our study was the overall weight gain across both treatment 
groups.  We asked the subjects to add the wine or the grape juice to the normal daily diet.  
Thus, it is not surprising to see this increase in weight gain as a result of added calories from 
the beverage.  Also, when body composition was further examined, there was no significant 
change seen in the total body fat percentage. If subjects gained weight, but the total body fat 
percentages were the same, the weight gain could be related to lean body mass gain. 
One interesting observation was that, when comparing the weight gain of WG with 
the weight gain in the JG, only WG was found to gain significantly more weight (P=0.027). 
However, when looking at the diet of each subject in both treatments, no significant 
difference was found on the macronutrients intake. Besides, the wine had slightly less 
calories than the grape juice. In addition, although not significant, a negative 0.45% change 
in total fat mass was found in the WG, while a positive 0.31% change was found in the JG. 
This suggested that red wine may have stronger ability in modulating body fat percentage 
compared to grape juice.  
 
The Effect of Red Wine and Grape Juice Consumption on Overall Heart Health 
 
One of the most interesting questions is whether drinking red wine and grape juice 
will pose health benefits to the human body. In our study, grape juice, although not 
significantly, conferred an increase on antioxidant capacity followed by acute consumption, 
as demonstrated by both FRAP and ORAC assays. The capability of grape juice to increase 
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antioxidant capacity was also clearly demonstrated by Day et al. (116). Red wine, on the 
other hand, was shown to significantly increase the plasma antioxidant capacity after 
consumption. These findings corroborate the research done by Whitehead and coworkers (4) 
who found a significant increase in antioxidant capacity of healthy adults after 1 hour and 2 
hours of red wine consumption when compared to baseline.  Although the effect caused by 
red wine consumption diminishes after several hours, this short-term increase in antioxidant 
capacity could have significant positive effect on human health.  An increase in antioxidant 
capacity may help the human body combat oxidation and enhance blood circulation. This 
could potentially create better passage for white blood cells to fight acute infection, enhance 
oxygen transmission through red blood cells during aerobic exercise, modulate blood 
pressure, and even enhance overall brain function. 
The French regularly consume wine with meals, typically 2-3 times a day. The 
reduced risk of cardiovascular disease in the “French Paradox” may be related to this 
drinking pattern. Our study only required subjects to consume 300 mL of red wine per day 
and did not specify a certain time interval. It is highly likely that the subjects had varying 
degrees of habits regarding the time the red wine was consumed. As antioxidant capacity is 
enhanced for a short period with each intake, it is possible that small doses of red wine intake 
during regular intervals throughout the day may further enhance potential health benefits 
which deserves further research.    
In summary, our study supports that middle-aged or older individuals with increased 
risk of cardiovascular disease and no contraindications to alcohol use, may benefit from daily 
moderate red wine intake. Given that CHD is a major health concern, this finding could have 
significant implications for those suffering from diseases related to increased oxidative stress. 
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However, it is important that people with a history of alcohol abuse not be encouraged to 
continue their habit based on potential CHD benefits only. It is also important that people 
with significant weight issues be encouraged to reduce caloric intake and increase their 
physical activities if red wine is added to their diet. Health professionals should take care in 
evaluating every individual’s health situation and discussing with the patient both the adverse 
and potentially beneficial aspects of moderate drinking.
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CONCLUSION 
 
 
In this study, acute consumption of 300 mL of red wine increased plasma antioxidant 
capacity as evidenced by the FRAP assay in middle-aged, sedentary, overweight, and obese 
individuals. This investigation supports the hypothesis that consuming red wine may confer 
some health benefits due to this increase. However, acute consumption of 300 mL of grape 
juice, or two weeks of red wine or grape juice consumption, did not significantly alter plasma 
antioxidant capacity. 
Because neither chronic nor acute consumption of grape juice yielded significant 
changes in the plasma antioxidant capacity, this study suggests that some compound in the 
wine, such as the alcohol, may help the absorption or change the metabolism of the phenolic 
compounds in human bodies. It is questionable whether grape juice, or any beverages or food 
with phenolic compounds, when paired with other types of alcohol, will yield the same result 
as red wine because the main difference between the two beverages is the alcohol content. 
Future research should examine the optimal amount of alcohol, if any, that will alter the 
changes in plasma antioxidant capacity followed by consumption of phenolic compounds. 
In addition, since this is one of the very first studies to investigate the difference 
between the effects of chronic versus acute red wine consumption in human subjects, and 
since our research showed that only acute consumption of red wine increased plasma 
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antioxidant capacity, more research needs to be done to elucidate the best frequency of red 
wine consumption in order to confer potential health benefits. Future research should look 
further at how the plasma antioxidant capacity peaks and decreases after consuming red wine 
as well as using a direct and sensitive marker of oxidative stress damage such as F2-
isoprostanes. 
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SUGGESTIONS FOR FUTURE RESEARCH DESIGN 
 
 
This research design could be strengthened by:  
1. Adding another treatment group using a resveratrol supplement of 87 mg;  
2. Adding another treatment group using the same grape juice with added alcohol; 
3. Measuring the antioxidant concentration and antioxidant capacity of all beverages in 
vitro and correlate results with plasma antioxidant concentration and capacity;  
4. Measuring plasma antioxidant capacity of the subjects for multiple times after acute 
consumption (30 minutes, 1 hour, 2 hours and 2.5 hours post consumption); 
5. Monitoring physical activity; 
6. Monitoring total body fat percentage as well as muscle mass changes; 
7. Developing different drinking patterns for subjects (with and without meals);  
8. Lengthening the duration of chronic consumption; and 
9. Increasing sample sizes. 
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APPALACHIAN STATE UNIVERSITY  
  
Informed Consent for Subjects in Research Projects Involving Human Subjects  
  
Title of Project:  Effect of chronic and acute red wine consumption on selected risk factors 
for disease, oxidative stress, and plasma antioxidant capacities  
 
      Primary Investigator: Tim L. Radak, Dr.P.H., RD  
      Co-investigators:  Lisa McAnulty, Ph.D., RD 
    Steven R. McAnulty, Ph.D. 
 
 
Purpose of this Research/Project   
 
  The purpose of this novel study is to examine the effects of chronic (2 wks) and  
acute (within 1 hr) consumption of 300 mL of red muscadine wine or dealcoholized wine  
on weight loss, body fat, illness rate, blood lipids, blood antioxidant capacity and  
phenols, and blood oxidative stress in 35 obese individuals.  This study is novel in that it  
will be the first study to incorporate all prior stated parameters in one study.  Given the  
prevalence of obesity in our country and particularly within our state, and increased  
oxidative stress in obese individuals, this project is highly relevant and will target a  
sizable section of the population. 
 
 
I. BRIEF REVIEW  
 
Obesity 
 
  Individuals with high body mass index (BMI) and obesity are prone to early  
mortality. Obesity is a well-established risk factor for hypertension, hyperlipidemia, type  
II diabetes, coronary heart disease, stroke, obstructive sleep apnea, asthma, orthopedic  
disorders, and certain cancers.  Despite this risk, the prevalence of obesity continues to  
increase worldwide, and there is a growing demand for safe and effective anti-obesity  
drugs. Previous anti-obesity drugs or anorexigens, particularly centrally acting agents,  
have poor safety records (13).  Red wine naturally contains high  
amounts of polyphenolic compounds which may be effective at reducing body fat and  
weight without the dangerous side effects associated with prescription drugs (5,15,16).   
 
Blood Antioxidant Capacity 
 
Phenolic compounds in red wine can exert antioxidant effects.  This has led to 
speculation that red wine consumption provides unique anti-atherosclerotic effects compared to 
other alcoholic beverages. However, studies assessing the effects of red wine consumption on 
plasma antioxidant capacity and oxidative stress in humans have not been conclusive regarding 
this issue (2,12,14,20,22).  These inconsistencies in outcome may have been due to use of 
different wine types, duration of supplementation, and amounts of supplementation.  
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Blood Oxidative Stress and Red Wine Polyphenolic Compounds 
 
 There is evidence that at least part of the process responsible for several of the major 
diseases known to contribute to mortality in the United States (for example, heart disease, cancer, 
diabetes, and Alzheimer’s) is related to oxidative stress and inflammation.  Oxidative stress is 
derived from the formation of compounds known as reactive oxygen species (ROS).  Research 
has shown supplementation with naturally occurring polyphenolic compounds to be safer than 
traditional antioxidants and exert many positive effects.  Dietary bioactive compounds from 
different functional foods, herbs and nutraceuticals (resveratrol, ginseng, ginkgo, nuts, grains, 
tomato, soy phytoestrogens, curcumin, melatonin, polyphenols, antioxidant vitamins, carnitine, 
carnosine, ubiquinone, etc.) may ameliorate or possibly even prevent diseases The action of 
polyphenols involves antioxidant activities, mitochondrial stabilizing functions, metal chelating 
activities, inhibition of cell death, and the killing of cancer cells. Functional foods and 
nutraceuticals constitute a great promise to improve health and prevent aging-related chronic 
diseases (3,6,17-19). 
Resveratrol, a natural antioxidant and polyphenol found in red wine and grapes, has been 
found to pharmacologically upregulate nitric oxide (NO), and possess anti-inflammatory, 
anticarcinogenic, and antioxidant activities (10). Studies have been conducted suggesting that 
pharmacologic doses of resveratrol protects heart (1), and brain tissue from oxidative stress(4), 
and is able to kill cancer cells (9).  Resveratrol appears able to enhance cellular protection by 
inducing production of existing cellular antioxidant systems (10).  Despite the quantity of work 
demonstrating beneficial effects of resveratrol, human studies are virtually non-existent.  A 
human subject study by Zern et al. (23) found that grape polyphenols beneficially affected key 
risk factors for coronary heart disease such as lipoprotein metabolism, oxidative stress, and 
inflammatory markers in both pre- and postmenopausal women.   
 
 
II. PROCEDURES  
 
One to two weeks prior to beginning the study, subjects will report to the ASU Human 
Performance Lab (054 Holmes Convocation Center) for baseline blood draw, orientation, 
screening, obtain informed consent, body composition, height, weight, and blood pressure.  Body 
composition (% body fat) will be determined using bioelectrical impedance (BIA).  Body 
composition, including % body fat will also be assessed via dual energy x-ray absorptiometry 
(DEXA).  These methods are administered routinely and safely within our lab. Changes in arterial 
flow and elasticity will also be measured at Baseline and pre acutely after two weeks 
consumption and post acute consumption for each group using the Sphygmacor Cardiovascular 
Management System Arterial Pulse Wave Velocity and Aortic Blood Pressure Waveforms.  This 
assessment of blood flow is completely safe, painless, and non-invasive.  All measurements will 
be conducted in accordance with guidelines set forth by the Clinical Application of Arterial 
Stiffness, Task Force III. Upon reporting to the lab, subjects will sit quietly for 10 min and be 
instructed not to consume alcohol or other drugs 24 hours prior to reporting and to avoid caffeine 
use the morning of reporting to the lab.  Subjects must agree to avoid the use of large-dose 
vitamin/mineral supplements (above 100% of recommended dietary allowances) and all herbs 
and medications during the study period.  Each subject will keep a 3-day food record prior to each 
test and be encouraged to maintain normal dietary patterns during the study.  During orientation, 
a dietitian will instruct the subjects on how to adhere to the dietary restrictions and how to record 
intake in a food record.   
Subjects will perform two trials in a randomized crossover design: 1) Wine (W) –
Subjects will consume 300 mL of Duplin red wine each night for 2 weeks and then report to the 
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laboratory in the morning for an acute episode of drinking 300 mL and having blood obtained 
within 1-h after consumption.  2) Dealcoholized Wine (DW) - Subjects will consume 300 mL of 
dealcoholized Duplin red wine each night for 2 weeks and then report to the laboratory in the 
morning for an acute episode of drinking 300 mL and having blood obtained within 1-h after 
consumption.  A two week wash out time period will separate trials.  To insure safety, subjects 
will remain in the lab for 2-h after the acute consumption at the ASU physiology lab before being 
allowed to leave.  This should allow blood alcohol levels to reach legal limits.   
Blood samples will be drawn three times for each trial which includes Baseline, Post 2 
wks chronic consumption, and 1-h post acute consumption.   The following tubes of blood will be 
drawn: Two x 5 mL EDTA tubes to assess plasma antioxidant capacity (FRAP and ORAC), one x 
5 mL serum separator for blood lipids, one x 5 mL serum separator for C-reactive protein, and 
one x 5 mL serum separator for iron binding capacities.  This is a total of about 25 mL of blood 
per draw and is far beneath what is typically obtained during a blood donation.   
 
 
III. RISKS 
  
The risks related to blood sampling will be minimized by having trained technicians 
perform the procedures.  Nonetheless, there is a small risk of infection or bruising.  The 
procedures are identical to those successfully used in a prior study.  Our collaborating physician 
is on call and available by phone.  The local rescue squad is 1 mile from our lab, with a 
documented response time of 2-3 minutes. All subjects will be provided instructions for care as 
well as contact phone numbers for the physician involved in the study and the principal 
investigator.  Universal precautions will be used throughout all blood collections.  This refers to a 
“mindset” or “attitude” taken by the researchers that assumes all blood or body tissues are 
potentially infectious.  In the case of exposure of an experimenter by your blood or tissue, that 
blood will be analyzed for HIV and hepatitis (a positive HIV or hepatitis test will be reported to 
the subject).   
 The measurement of your body composition via BIA and dual energy x-ray 
absorptiometry will expose you to a small dose of electricity and radiation, respectively. This 
study involves a small radiation exposure that is less than other diagnostic tests involving 
radiation exposure. For example, the amount of radiation exposure received in this study is below 
that which you would receive from a CT scan, and well below the amount that poses a significant 
risk of harm. The total amount of radiation exposure is equivalent to the exposure you would 
receive in a cross-country airplane flight and present no additional risk to you. Changes in arterial 
flow and elasticity measured using the Sphygmacor Cardiovascular Management System Arterial 
Pulse Wave Velocity and Aortic Blood Pressure Waveforms assessment of blood flow is 
completely safe, painless, and non-invasive.  A small pen-like probe is placed over your carotid 
artery (side of your neck), over the femoral artery (top of your leg) and ankle artery.  A transducer 
(like a microphone) uses ultrasound waves (sound waves which bounce off the blood in the blood 
vessel) to measure the speed and direction of blood flow through an artery.  No physical 
discomfort should be experienced during this test.  Your privacy will be upheld with great care 
during the assessment of the femoral artery, as this is best located near the pubic area.  There are 
no known risks associated with the Doppler ultrasound used in this technique. 
 The alcohol consumed on a daily basis in this study is considered modest and has been 
safely used in a prior research project (11).  However unlikely, we will ask subjects to report any 
adverse symptoms associated with the amount of wine used in this study such as unusual nausea, 
headache, vomiting, weakness, or mental confusion Subjects will be given the contact 
information for the lead investigator in case of questions or problems.  Excessive alcohol 
consumption associated with alcoholism is well understood to be detrimental both 
psychologically and physically.  Individuals identified to have alcohol problems will not be 
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included in this study.  Furthermore, subjects will be required to remain in the ASU laboratory for 
2-h following the acute wine consumption to insure a return to legal alcohol limits before being 
allowed to leave. 
 
 
IV. BENEFITS 
  
 The subject will receive results of all tests, with counseling given regarding implications 
for nutrition.  I understand that no promise or guarantee of benefits have been made to encourage 
participation.  Larger societal benefits include potential progress toward methods to minimize 
detrimental effects from oxidative stress associated with certain disease processes.    
 
 
V. EXTENT OF ANONYMITY AND CONFIDENTIALITY  
  
 The identity of subjects will not be disclosed in any published documents or shared with 
anyone but the experimenters. 
 
 
VI. COMPENSATION  
  
None. If as a result of a research project, the investigator determines that the subject 
should seek counseling or medical treatment, a list of local services will be provided. In the event 
of physical injury resulting from the research procedures, immediate first-aid is provided free of 
charge. No funds have been set aside for medical treatment of any injury or illness resulting from 
this project. 
 
 
VII. FEEDOM TO WITHDRAW  
  
  The subject is free to withdraw from this study at any time without penalty.   
 
VIII. Approval of Research   
  
This research project has been approved, as required, by the Institutional Review Board 
of Appalachian State University.  
 
 
 _3-4-09______________________     _3-3-2010____________________________ 
 IRB Approval Date                               Approval Expiration Date 
 
 _09-0186______________________      
 Study #:  
 
 
 
 
 
 
IX. Subject's Responsibilities  
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I voluntarily agree to participate in this study. I have the following responsibilities: 
 
1.  The subject will attend an orientation session in the ASU Human Performance Laboratory 
prior to the start of the study. 
 
2.  The subject will eat a diet conforming to a food list (as described by the study dietitian) during 
the week period prior to and during the three weeks of the study period.  
  
3.  The subject agrees to be randomized into either: 1) Red wine – Drink 300 mL red wine each 
day for 14 days and come to the ASU laboratory on the 15
th
 day and drink 300 mL of red wine.  
Then, remain in the lab for 2-h afterwards for safety reasons.  2) Dealcoholized red wine - Drink 
300 mL dealcoholized red wine each day for 14 days and come to the ASU laboratory on the 15
th
 
day and drink 300 mL of dealcoholized red wine.  Then, remain in the lab for 2-h afterwards for 
safety reasons.  While a subject in this project, subjects agree to avoid the use of large-dose 
vitamin/mineral supplements (above 100% of recommended dietary allowances), herbs, and 
medications purported to be antioxidants or affect oxidative stress.  Body composition (% body 
fat) will be determined using BIA and DEXA at Baseline and Pre-acute session.  Blood pressure 
measurements will be obtained at each blood draw.   
 
4.  On the day of acute testing and prior to the test, subjects will not eat anything past midnight 
the previous day before coming to the lab.   
 
7.  Blood samples will be collected at baseline, 2 wks post, and 1-h after acute drink on each of 
the two test sessions.  
 
8. Females will not be pregnant upon entering the study and throughout the study time period. 
X. Subject's Permission (May be modified in the case of minors or members of other vulnerable 
populations.)  
  
I have read and understand the Informed Consent and conditions of this project. I have had all my 
questions answered. I hereby acknowledge the above and give my voluntary consent:   
 _________________________________________________Date__________  
Subject signature  
  ________________________________________________ Date __________  
 Witness (Optional except for certain classes of subjects)  
  
 Should I have any questions about this research or its conduct, I may contact:  
 Tim Radak                             828-262-2631                        radaktl@appstate.edu  
Primary Investigator    Office Phone                                   e-mail 
Jay Cranston                          828-262-2692                      johnsonrl@appstate.edu  
Administrator, IRB                            Telephone                                  e-mail  
Graduate Studies and Research  
Appalachian State University  
Boone, NC  26608  
Subjects must be given a complete copy (or duplicate original) of the signed Informed 
Consent. 
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APPENDIX B 
Recruitment Flier of the Wine and Grape Juice Study 
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APPENDIX C 
Randomized Crossover Design
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APPENDIX D 
Health Questionnaire 
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Subject ID: _______________________     Interviewer’s Name:__________________ 
Subject’s Name:____________________     Date (mm/dd/yy):____________________ 
HEALTH AND MEDICAL HISTORY QUESTIONNAIRE 
BACKGROUND 
1. What is your highest level of education? 
  __Elementary  __Jr High School __High School  __College __Post College 
2. What is your ethnic background? 
 __Hispanic or Latino (Cuban, Mexican, Puerto Rican, South or Central American, or other Spanish origin) 
__Not Hispanic or Latino 
3. What is your race? __White (Europe, the Middle East, or North Africa) __ African American __ Asian
   __ Native Hawaiian/Pacific Islander __ American Indian/Alaska Native 
OVERALL HEALTH 
4. How would you rate your present health condition? 
  __Poor  __Fair  __Good __Excellent 
5. Typically, how many days/year are you sick enough to stay in bed?___________ 
WEIGHT HISTORY 
6. Has your weight changed more than 10 lbs in the last 12 months? __Yes __No 
 If yes, why: 
 __change in diet __change in physical activity __illness __depression/stress __other 
7. Do you have a history of an eating disorder, such as anorexia or bulimia? __No __Yes 
8. Have you ever smoked? 
 __Never __Not now, but more than 12 months ago __Not now, but within the past 12 months 
 __Yes, currently smoking 
MEDICAL HISTORY 
9. Please check which of the following conditions you have had or now have.  Also check medical conditions in your  
family (father, mother, brother(s), or sister(s)). Check as many as apply 
 Personal Family  Medical History 
  □ □  Coronary heart disease, heart attack 
  □ □  Surgery 
  □ □  Angina 
  □ □  High blood pressure 
  □ □  Peripheral vascular disease 
  □ □  Phlebitis or emboli 
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HEALTH AND MEDICAL HISTORY QUESTIONNAIRE 
 Personal Family  Medical History 
 
  □ □  Other heart problems (specify:_________________) 
  □ □  Lung cancer 
  □ □  Breast cancer 
  □ □  Prostate cancer 
  □ □  Colorectal cancer 
  □ □  Skin cancer 
  □ □  Other cancer (specify:________________) 
  □ □  Stroke 
  □ □  Chronic obstructive pulmonary disease (emphysema) 
  □ □  Pneumonia 
  □ □  Asthma 
  □ □  Bronchitis 
  □ □  Diabetes mellitus 
  □ □  Thyroid problems 
  □ □  Kidney disease 
  □ □  Liver disease (cirrhosis of the liver) 
  □ □  Hepatitis (A,B,C,D, or E) 
  □ □  Gallstones/gallbladder disease 
  □ □  Osteoporosis 
  □ □  Arthritis 
  □ □  Gout 
  □ □  Anemia (low iron) 
  □ □  Stomach/duodenal ulcer 
  □ □  Rectal growth or bleeding 
  □ □  Cataracts 
  □ □  Glaucoma 
  □ □  Depression 
  □ □  Substance abuse problems (alcohol, drugs etc) 
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HEALTH AND MEDICAL HISTORY QUESTIONNAIRE 
 
 
10. Please indicate the approximate number of alcoholic beverages per every two weeks. (Beer: 
 one drink = one 12-ounce beer; Liquor: One drink = 1.5 ounces of liquor; Wine: One drink = 5 ounces) 
  □ 0 Drinks 
  □ 1-2 Drinks 
  □ 3 or more Drinks 
 
11. Please check any of the following medications (prescription and/or over the counter) you currently take 
regularly. Also give the name of the medication. 
   Medication   Name of Medication 
  □ Heart Medicine  __________________ 
  □ Blood Pressure Medicine __________________ 
  □ Blood cholesterol Medicine __________________ 
  □ Hormones   __________________ 
  □ Birth Control pills  __________________ 
  □ Medicine for breathing/lungs __________________ 
  □ Insulin    __________________ 
  □ Other medicine for diabetes __________________ 
  □ Arthritis Medicine  __________________ 
  □ Medicine for depression __________________ 
  □ Medicine for anxiety  __________________ 
  □ Thyroid Medicine  __________________ 
  □ Medicine for Ulcers  __________________ 
  □ Pain killer Medicine  __________________ 
  □ Allergy Medicine  __________________ 
  □ HIV/AIDS Medicine  __________________ 
  □ Hepatitis Medicine  __________________ 
  □ Other (please specifiy)  __________________ 
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HEALTH AND MEDICAL HISTORY QUESTIONNAIRE 
 
Supplement Use 
12. Are you presently using or have you used within the last 12 months the following supplements at least three  
      times/week: 
Type of Dietary Supplement 
 
Note:  If calcium and vitamin D are 
taken as one supplement, separate 
into two categories under "single 
vitamin" and "single mineral". 
If a supplement contains more than 3 
components, enter as either 
"multivitamin", "multimineral", or 
"multivitamin/mineral". 
Provide Brand Name 
or Type (i.e., vitamin E, 
calcium, iron, etc.) 
Add important 
comments 
Use Dosage/Tab 
(single 
substances) 
& Units 
Cups for 
herbal teas 
Spoons or 
scoops for 
some 
No. 
Tabs 
per time 
point 
No. 
Times: 
Per day 
or 
Per week 
Last Used 
(mm/yyyy) 
Multivitamin     NA 
      
Multimineral     NA 
      
Multivitamin/mineral     NA 
      
Single vitamin(s)      
      
      
      
      
Single mineral(s)      
      
      
      
      
Herbal dietary supplement(s)      
      
      
      
Herbal tea*  NA    
      
      
Other over-the-counter 
supplement(s) 
     
      
      
      
Fiber Supplement (i.e., 
Metamucil, Fibercon) 
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HEALTH AND MEDICAL HISTORY QUESTIONNAIRE 
 
 
Physical Fitness, Physical Activity/Exercise 
13.   In general, compared to other persons your age, rate how physically fit you are: 
 1 □  2 □  3 □  4 □  5 □  6 □  7 □  8 □  9 □  10 □ 
 Not at all      Somewhat               Extremely 
 Physically active     physically active              physically fit  
 
 
 
14. Outside of your normal work or daily responsibilities, how often do you engage in exercise that at least moderately  
increases your breathing and heart rate, and makes you sweat, for at least 20 minutes (such as brisk walking, 
cycling, swimming, jogging, aerobic dance, stair climbing, rowing, basketball, racquetball, vigorous yard work, etc.) 
 
 □ 5 or more times per week □ 3 to 4 times per week □ 1 to 2 times per week 
 □ Less than 1 time per week  □ Seldom or never 
 
15. How much hard physical work is required on your job? 
 □ A great deal □ A moderate amount   □ None 
 
16. How long have you exercised or played sports regularly? 
 
 □ I do not exercise regularly □ less than 1 year □ 1 to 2 years 
 □ 2-5 years  □ 5-10 years    □ more than 10 years 
 
 
 
 
 
 
 
 
Name of personal physician:___________________________________  Phone #:_______________________ 
 
Address:_______________________________________________________________________________________ 
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APPENDIX E 
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RED WINE STUDY INSTRUCTIONS 
ORIENTATION DATE: Saturday April 4, 2009  
TIME: 8 a.m. 
LOCATION:  
 Holmes Convocation Center (Department of Health, Leisure and Exercise Science) 
on Rivers St.  You may enter the double doors on Rivers St and turn left at the 
information desk and the lab will be on the right.   
 If you need further directions, please email or call me at 423-361-2239. 
 
DURING ORIENTATION: Subjects will sign consent forms, answer health questionnaires, 
undergo an initial screening (height, weight, etc), blood pressure, diet instruction for 3 day 
food records, DEXA scan, and blood draws. 
WHAT TO WEAR:  
 Please wear loose fitting clothes such as sweatpants, lounge pants, shorts, t-shirts, 
etc.   
 Also, minimal jewelry is recommended.  Jewelry cannot be worn during the DEXA 
scan.   
 Be consistent in what you wear each time you come to the lab. 
 
HOW TO PREPARE:  Each time you come to the lab for testing and for orientation you need 
to be fasted.  You will need to fast after midnight the night before you come to lab.  The 
orientation session should last about 2 hours. 
WHAT TO STOP:  
 You will need to stop any mega-dose supplements (>100% RDA) beyond what is in 
a multivitamin.  
 Do not drink any additional wine, white or grape juice during the study other than 
what you are given.  
 Do not consume fruits or fruit juices 3 days before coming in for testing or orientation.  
Vegetables are ok. 
 
ALLERGY: Please let me know if you have a sulfite allergy.  Wine is known to possibly 
contain sulfites. 
You will be given during orientation the other dates and times you will need to come to the 
lab. 
We look forward to seeing you! 
If you have any questions, please contact Dr Lisa McAnulty at 828-773-0251 or 
mcanultyl@appstate.edu.  Thank you.
    
 
63 
 
Appalachian State University Wine and Grape Juice Study 
Departments of Family and Consumer Sciences and Health Leisure and Exercise Science 
 
What To Do When Home 
 
 Be consistent with each day when you consume wine (i.e. after evening meal) 
 
 You may consume two 150-mL portions together or separately 
 
 Wine and grape juice is best if served chilled 
 
 Do not store in direct sunlight or heat – keep wine bottles cold. Once opened, put in 
refrigerator 
 
 You will need a wine opener 
 
 You have been given enough wine/juice to provide two 150-mL servings per day; 
however, bottle six will roughly be half full. Please return all six bottles at next testing 
visit 
 
 At your next visit, don’t forget to bring your Food Records Sheet and to arrive 
‘fasted’.  
 
 If you have any questions or any doubt about what to do call us anytime at:   
Dr. Lisa McAnulty 828-773-0251. 
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Food Recording Form 
(Please fill in and bring with you on April 19
th 
at 8:00 am) 
 
Name ______________________________    Age __________ 
Mailing Address __________________________________________________________ 
________________________________________________________________________ 
Height ______________     Weight ________________    Gender ________________ 
Current e-mail address:  ____________________________________________________ 
Directions for Using the Food Diary 
 
1. Please record ALL food, beverage, and supplements eaten/ingested for three days:  
Monday, Wednesday, and Saturday (April 13, 15, 18).  These three days should be as typical 
as possible. 
 
2. To reduce error, please follow these directions: 
a. Keep your food diary current (list foods immediately after they are eaten). 
b. Whenever possible, MEASURE the volume consumed by using cups and 
tablespoons.  Record amounts in household measures---ounces, tablespoons, cups, 
and slices. 
c. Be specific when describing the foot item eaten, and the method that was used to 
prepare the food.  Remember to include condiments, sugar, oils, butter, and other 
visible fats  For example: 
Apple, raw, fresh, with peel     1 medium 
Bread, whole wheat, fresh      2 slices 
Margarine, soft from tub   1 tablespoon 
Cereal, corn flakes   1.5 cups 
Sugar, white    1 teaspoon 
Milk, non fat    2 cups 
Fish, salmon, baked   10 ounces 
 
d. This food record will be analyzed with a computerized dietary analysis program, and 
the report will be sent to you with an explanation of the results. 
 
 
 
65 
 
Time 
Food/Beverage 
Consumed 
Food Item and Method of Preparation Amount Eaten 
(in cups, tablespoons, 
ounces, etc.) 
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APPENDIX F 
Collected Data
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Descriptive and Weight 
 
68 
 
Body Fat Percentage 
 
69 
 
C-Reactive  Protein 
 
70 
 
Total Cholesterol 
 
71 
 
HDL 
 
72 
 
LDL 
 
73 
 
Triglyceride 
 
74 
 
FRAP 
 
75 
 
ORAC 
 
    
 
76 
 
APPENDIX G 
Nutrition Information of the Red Wine and the Grape Juice Used
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Nutrition Information of the Red Wine and the Grape Juice Used 
 
Hatteras Red - Duplin Winery (Rose Hill, NC) 
INGREDIENTS:  100% Muscadine grapes 
  
Serving Size:  4 fl oz (118 mL) 
Amount in one bottle:  750 mL 
  
Amount per serving: 
Calories:  76.8 
Total Fat:  0g 
Total Carbohydrate:  19.2 g 
     Sugars 
     Sugar Alcohols 
Protein:  0g 
Acid level:  0.67% 
Resveratrol content:  73.39 parts per million (this is an estimate) 
 
100% Muscadine Grape Juice - D’Vine Foods (Elizabethtown, NC) 
  
INGREDIENTS:  100% Muscadine grape juice, may contain sulfites 
  
Serving size:  4 fl oz (118 mL) 
Servings per container:  6.25 
  
Amount per serving: 
Calories:  80 
Calories from Fat:  5 
Total Fat:  0 g 
        Saturated Fat:  0 g 
        Trans Fat:  0 g 
Total Carbohydrate:  22 g (7% daily value) 
       Dietary Fiber:  1 g (4% daily value) 
       Sugars:  20 g 
Protein:  1 g 
Cholesterol:  0 mg 
Sodium:  0 mg 
 
  
Vitamin A:  2%                     Vitamin C:  8% 
Calcium:  2%                        Iron:  2% 
  
Percent daily values are based on a 2,000 calorie diet. 
*Resveratrol content not available from company 
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